Bristol-Myers Squibb Stock Forecast for 2022 - 2025 - 2030

Updated on 09/27/2022

Stock Rating
2
Price Target
$83.00
Consensus
Outperform
Upside
18.32%
Analysts
16
Stock Rating
2
Upside
18.32%
Analysts
16
Price Target
$83.00

Bristol-Myers Squibb Stock Forecast and Price Target

If the average 2022 price target of $83.00 recently set by sixteen prominent experts for Bristol-Myers Squibb is met, there would be a potential upside of approximately 18.32% from the last closing price in September, 2022. The high estimate is $94.00, and the low is $61.00. If you're looking for information on Bristol-Myers Squibb stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.

$83.00

18.32% Upside

Outperform
Outperform

Bristol-Myers Squibb Fair Value Forecast for 2022 - 2025 - 2030

In the last three years, Bristol-Myers Squibb's Price has grown, rising from $48.28 to $91.10 – a growth of 88.69%. In the next year, analysts believe that Fair Value will reach $93.89 – an increase of 3.06%. By 2030, professionals predict that Bristol-Myers Squibb's Fair Value will decrease by 8.79%, to $83.09.

2022 Fair Value Forecast
$93.89
2023 Fair Value Forecast
$99.83
2024 Fair Value Forecast
$103.23
2025 Fair Value Forecast
$107.84
2026 Fair Value Forecast
$103.47
2027 Fair Value Forecast
$100.07
2028 Fair Value Forecast
$96.19
2029 Fair Value Forecast
$88.06
2030 Fair Value Forecast
$83.09
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 12
$165.70 $185.07 9.84%
LLY Stock Forecast Eli Lilly and Outperform 16
$307.50 $333.19 13.82%
ROG Stock Forecast Roche Holding Outperform 18
CHF305.90 CHF384.23 22.59%
ABBV Stock Forecast AbbVie Outperform 9
$141.21 $164.23 10.47%
PFE Stock Forecast Pfizer Outperform 3
$43.83 $56.27 20.92%

Bristol-Myers Squibb Revenue Forecast for 2022 - 2025 - 2030

In the last three years, Bristol-Myers Squibb's Revenue has grown, rising from $22.56B to $46.39B – a growth of 105.60%. In the next year, analysts believe that Revenue will reach $47.10B – an increase of 1.55%. By 2030, professionals predict that Bristol-Myers Squibb's Revenue will decrease by 20.45%, to $36.90B.

2022 Rev Forecast
$47.10B
2023 Rev Forecast
$48.66B
2024 Rev Forecast
$50.13B
2025 Rev Forecast
$51.08B
2026 Rev Forecast
$49.48B
2027 Rev Forecast
$47.55B
2028 Rev Forecast
$43.96B
2029 Rev Forecast
$39.19B
2030 Rev Forecast
$36.90B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
MRK Stock Forecast Merck Outperform 6
$86.18 $99.57 16.04%
NOVO B Stock Forecast Novo Nordisk A/S Outperform 18
kr741.60 kr678.96 20.69%
DHR Stock Forecast Danaher Outperform 16
$262.66 $321.60 23.73%

Bristol-Myers Squibb Dividend per Share Forecast for 2022 - 2025 - 2030

Bristol-Myers Squibb's Dividend per Share has grown In the last three years, rising from $1.61 to $2.01 – a growth of 24.84%. In the next year, analysts believe that Dividend per Share will reach $2.13 – an increase of 5.97%. For the next nine years, experts predict that Bristol-Myers Squibb's Dividend per Share will grow at a rate of 4.48%.

2022 DPS Forecast
$2.13
2023 DPS Forecast
$2.25
2024 DPS Forecast
$2.37
2025 DPS Forecast
$2.44
2026 DPS Forecast
$2.45
2027 DPS Forecast
$2.10
2028 DPS Forecast
$2.10
2029 DPS Forecast
$2.10
2030 DPS Forecast
$2.10
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
AZN Stock Forecast AstraZeneca PLC Outperform 18
£99.33 £136.08 43.33%
NOVN Stock Forecast Novartis Hold 18
CHF73.98 CHF103.75 20.40%
AMGN Stock Forecast Amgen Hold 9
$226.87 $246.51 12.40%

Bristol-Myers Squibb Free Cash Flow Forecast for 2022 - 2025 - 2030

In the last three years, Bristol-Myers Squibb's Free Cash Flow has grown by 149.13%, rising from $6.12B to $15.23B. For the next year, analysts predict that Free Cash Flow will reach $20.19B – an increase of 32.50%. In 2030, professionals predict that Bristol-Myers Squibb's Free Cash Flow will decrease by 2.26%, reaching $14.89B.

2022 FCF Forecast
$20.19B
2023 FCF Forecast
$19.68B
2024 FCF Forecast
$19.61B
2025 FCF Forecast
$19.19B
2026 FCF Forecast
$19.10B
2027 FCF Forecast
$17.17B
2028 FCF Forecast
$16.36B
2029 FCF Forecast
$15.84B
2030 FCF Forecast
$14.89B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
MDT Stock Forecast Medtronic Outperform 18
$81.33 $106.84 30.33%
SAN Stock Forecast Sanofi Outperform 18
77.44€ 104.66€ 42.05%
GILD Stock Forecast Gilead Sciences Outperform 11
$62.34 $69.65 13.89%

Bristol-Myers Squibb Net Income Forecast for 2022 - 2025 - 2030

Bristol-Myers Squibb's Net Income has seen impressive growth In the last three years, rising from $4.92B to $6.99B – a growth of 42.15%. In the next year, analysts believe that Net Income will reach $16.50B – an increase of 135.92%. For the next nine years, the forecast is for Net Income to grow by 90.07%.

2022 NI Forecast
$16.50B
2023 NI Forecast
$17.26B
2024 NI Forecast
$17.43B
2025 NI Forecast
$17.87B
2026 NI Forecast
$17.08B
2027 NI Forecast
$16.55B
2028 NI Forecast
$15.67B
2029 NI Forecast
$14.22B
2030 NI Forecast
$13.29B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
REGN Stock Forecast Regeneron Pharmaceuticals Outperform 2
$686.10 $696.64 10.48%
MRK Stock Forecast MERCK Kommanditgesellschaft au... Outperform 18
158.55€ 147.51€ 32.45%
MMM Stock Forecast 3M Hold 16
$113.00 $147.79 21.24%

Bristol-Myers Squibb EBITDA Forecast for 2022 - 2025 - 2030

In the last three years, Bristol-Myers Squibb's EBITDA has grown, moving from $5.87B to $20.58B – an increase of 250.70%. In the next year, analysts predict that EBITDA will jump to $21.39B – up 3.95% from the current level. By 2030, professionals believe that Bristol-Myers Squibb's EBITDA will have decreased by 32.53%, falling to $13.89B.

2022 EBITDA Forecast
$21.39B
2023 EBITDA Forecast
$21.50B
2024 EBITDA Forecast
$21.76B
2025 EBITDA Forecast
$21.84B
2026 EBITDA Forecast
$22.73B
2027 EBITDA Forecast
$19.18B
2028 EBITDA Forecast
$18.16B
2029 EBITDA Forecast
$14.60B
2030 EBITDA Forecast
$13.89B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
GSK Stock Forecast GSK Outperform 16
£13.25 £16.08 43.02%
BAYN Stock Forecast Bayer Outperform 7
48.37€ 67.79€ 64.36%
4519 Stock Forecast Chugai Pharmaceutical Hold 18
¥3.42k ¥0.00 31.66%

Bristol-Myers Squibb EBIT Forecast for 2022 - 2025 - 2030

In the last three years, Bristol-Myers Squibb's EBIT has seen an increase, rising from $5.28B to $9.82B. This represents a growth of 86.09%. Analysts predict that Bristol-Myers Squibb's EBIT will increase in the upcoming year, reaching $19.38B. This would represent an increase of 97.33%. Over the next nine years, experts predict that Bristol-Myers Squibb's EBIT will grow at a rate of 54.90%.

2022 EBIT Forecast
$19.38B
2023 EBIT Forecast
$20.34B
2024 EBIT Forecast
$20.77B
2025 EBIT Forecast
$21.43B
2026 EBIT Forecast
$20.31B
2027 EBIT Forecast
$19.04B
2028 EBIT Forecast
$18.30B
2029 EBIT Forecast
$16.43B
2030 EBIT Forecast
$15.21B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
A Stock Forecast Agilent Technologies Outperform 17
$122.31 $149.56 22.64%
BAS Stock Forecast BASF Outperform 11
39.81€ 78.27€ 38.16%
ILMN Stock Forecast Illumina Outperform 16
$184.12 $251.56 30.62%

Bristol-Myers Squibb EPS Price Prediction Forecast for 2022 - 2025 - 2030

In the last three years, Bristol-Myers Squibb's EPS has grown, rising from $3.98 to $7.51 – a growth of 88.69%. In the next year, analysts believe that EPS will reach $7.74 – an increase of 3.06%. By 2030, professionals predict that Bristol-Myers Squibb's EPS will decrease by 8.79%, to $6.85.

2022 EPS Forecast
$7.74
2023 EPS Forecast
$8.23
2024 EPS Forecast
$8.51
2025 EPS Forecast
$8.89
2026 EPS Forecast
$8.53
2027 EPS Forecast
$8.25
2028 EPS Forecast
$7.93
2029 EPS Forecast
$7.26
2030 EPS Forecast
$6.85
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BIIB Stock Forecast Biogen Outperform 11
$195.75 $242.78 16.22%
BAX Stock Forecast Baxter International Outperform 17
$54.91 $69.92 25.66%
4503 Stock Forecast Astellas Pharma Outperform 18
¥1.89k ¥0.00 27.05%